Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A recent market commentary from Yahoo Finance urged investors to look past Zepbound and toward Eli Lilly’s broader drug discovery engine, citing three newer medicines as potential drivers.
THE APEX TIMES
THE APEX TIMES
A European Medicines Agency panel has backed Eli Lilly’s Foundayo for obesity and type 2 diabetes, a move that could put the drug on track to compete with Novo Nordisk’s oral GLP-1 therapy in Europe’s emerging oral market.
THE APEX TIMES
An advisory committee under the European Medicines Agency recommended approval for Foundayo, the once-daily weight-loss pill from Eli Lilly, boosting market optimism around the company’s obesity franchise.
THE APEX TIMES
A reported block sale by the Lilly Foundation, Eli Lilly’s biggest shareholder, outlines potential portfolio rebalancing, but it does not by itself explain any change in company fundamentals.
THE APEX TIMES
The company says new clinical analyses show its Omvoh therapy helped patients achieve corticosteroid-free disease control at one year across difficult inflammatory bowel disease cases, with results reported for both ulcerative colitis and Crohn’s.
THE APEX TIMES
After a roughly 25% gain over six months, Eli Lilly has become the focus of renewed speculation about whether the company could pursue a stock split to make its shares more accessible to smaller investors.
THE APEX TIMES
The drugmaker said it will publish its third-quarter 2026 financial results on October 29, 2026, and hold a conference call with the investment community and media the same day.
THE APEX TIMES
The company highlighted additional composite outcomes from patients treated with its IL-23 targeted therapy, emphasizing steroid-free management and sustained remission measures across inflammatory bowel disease.
THE APEX TIMES
The Chinese biotech Adlai Nortye said it is partnering with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035 both alone and in combination with cetuximab in an ongoing global Phase I study.
